Metagenomi Therapeutics (MGX) Return on Capital Employed (2024 - 2026)
Metagenomi Therapeutics (MGX) reported Return on Capital Employed of 49.74% for Q1 2026, down 1742.0% year-over-year from 3.03% in Q1 2025, and down 9.61% quarter-over-quarter from 45.38% in Q4 2025.
Metagenomi Therapeutics (MGX) Return on Capital Employed (2024 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 3 years of Return on Capital Employed data on file, last reported at 49.74% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 49.74%, down 1742.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 49.74% (down 1742.0% YoY), and the FY2025 annual result was 38.42%, down 950.0% from the prior year.
- Return on Capital Employed eased to 49.74% in Q1 2026 per MGX's latest filing, from 45.38% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 25.44% in Q2 2024 and troughed at 49.74% in Q1 2026.
- A 3-year average of 34.86% and a median of 32.32% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 427 bps in 2025, then tumbled 1742 bps in 2026.
- A 3-year view of Return on Capital Employed shows it stood at 29.23% in 2024, then slumped by 55 bps to 45.38% in 2025, then slipped by 10 bps to 49.74% in 2026.
- Business Quant data shows MGX's Return on Capital Employed at 49.74% in Q1 2026, 45.38% in Q4 2025, and 40.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -50.43% |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -49.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.74% |
| Dec 31, 2025 | -45.38% |
| Sep 30, 2025 | -40.03% |
| Jun 30, 2025 | -36.46% |
| Mar 31, 2025 | -32.32% |
| Dec 31, 2024 | -29.23% |
| Sep 30, 2024 | -27.10% |
| Jun 30, 2024 | -25.44% |
| Mar 31, 2024 | -28.05% |